Proteins and Peptides

06 Oct 2016 Molecular Partners regains rights to multi-DARPin® drug candidate targeting IL-13 & IL-17 for pulmonary indications from Janssen
30 Sep 2016 CohBar Advances First-in-Class Mitochondria Based Therapeutic to IND-Enabling Activities
30 Sep 2016 Endo Pharmaceuticals Presents New Phase 2 Data Evaluating the Safety and Effectiveness of XIAFLEX® (Collagenase Clostridium Histolyticum) for Dupuytren's Disease Nodules
30 Sep 2016 Aurinia Announces That Voclosporin Achieves Primary and All Pre-Specified Secondary Endpoints in Its Phase IIb AURA-LV Study for Lupus Nephritis (LN)
27 Sep 2016 Amgen Announces Top-Line Results From Phase 3 KYPROLIS® (Carfilzomib) CLARION Study In Newly Diagnosed Multiple Myeloma Patients
26 Sep 2016 First Patient Dosed in CANbridge’s CAN-008 Phase I/II Trial in Newly-Diagnosed Glioblastoma Multiforme in Taiwan
26 Sep 2016 ERYTECH Completes Patient Enrollment in Phase 2 Trial of eryaspase (GRASPA) for Pancreatic Cancer
26 Sep 2016 Cinfa Biotech starts second clinical study of pegfilgrastim biosimilar candidate B12019
24 Sep 2016 Novo Nordisk submits application in the US for including data from the two SWITCH trials in Tresiba® label
22 Sep 2016 PharmaMar Submits MAA to EMA for Aplidin® for the Treatment of Multiple Myeloma
20 Sep 2016 Synthetic Biologics Announces Completion of Enrollment for Phase 2b Proof-of-Concept Clinical Trial for SYN-004 (ribaxamase) for the Prevention of Clostridium Difficile Infection, Antibiotic-Associated Diarrhea and the Emergence of Antibiotic-Resistant Or
20 Sep 2016 BioLineRx Announces Initiation of Phase 2a Trial of BL-8040 in Combination With KEYTRUDA® (pembrolizumab) for Treatment of Pancreatic Cancer
20 Sep 2016 Bexion Pharmaceuticals Doses First Patient in Phase I Trial of BXQ-350 For Patients with Advanced Solid Tumors at the University of Cincinnati Cancer Institute
19 Sep 2016 Stealth BioTherapeutics Reports Elamipretide Improved Skeletal Muscle Bioenergetics in the Elderly
17 Sep 2016 Phase III Combination Trial of BYDUREON and FARXIGA Shows Significant Blood Sugar Reduction in Patients with Type 2 Diabetes
16 Sep 2016 Semaglutide reduced major cardiovascular events by 26% in adults with type 2 diabetes at high cardiovascular risk
15 Sep 2016 BioMarin Announces EMA Validation of Brineura™ (Cerliponase Alfa) Marketing Authorization Application for Treatment of CLN2 Disease, a Form of Batten Disease
14 Sep 2016 Inotrem Successfully Completes Its First Phase I Clinical Trial with Motrem™, a TREM-1 Pathway Modulator for the Treatment of Septic Shock
13 Sep 2016 Sanofi's Fixed-Ratio Combination Helps More Patients Reach Mealtime Blood Sugar Target than Insulin Glargine Alone
13 Sep 2016 Semaglutide Demonstrated Superior HbA1c Reduction vs Placebo as Add-on to Basal Insulin Alone or with Metformin in Adults with type 2 Diabetes
13 Sep 2016 Stealth BioTherapeutics Initiates Phase 2 Study of Elamipretide in Primary Mitochondrial Disease
13 Sep 2016 Alizé Pharma III presents preclinical results from its I-HBD1 program at the Annual Meeting of the American Society for Bone and Mineral Research
09 Sep 2016 Emmaus Life Sciences Submits New Drug Application for Sickle Cell Disease Treatment
09 Sep 2016 Avelas Biosciences Completes Patient Enrollment for AVB-620 Phase 1b Clinical Trial
08 Sep 2016 La Jolla Pharmaceutical Company Reports Positive Results from Phase 1 Study of LJPC-401

La Merie Biologics

FREE Weekly News Bulletin

2016 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing